Low-Dose Naltrexone for Pruritus in Systemic Sclerosis

Int J Rheumatol
12 September 2011
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171757/

Low-Dose Naltrexone (LDN) Treatment for Crohn's Disease (CD): A Tertiary Care Center Experience

Am J Gastroenterol
October 2011
https://journals.lww.com/ajg/Fulltext/2011/10002/Low_Dose_Naltrexone__LDN__Treatment_for_Crohn_s.1223.aspx

Safety and tolerability of Low-Dose Naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study

J Clin Gastroenterol
01 April 2014
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586944/

Background
There is an unmet need for safe and effective medicines to treat children with Crohn’s disease. Recently, investigations have shown an association between endogenous opioid peptides and inflammatory cells.

P388 Immunological changes in IBD patients responding to low-dose naltrexone treatment

J Crohn's and Colitis
01 February 2012
https://academic.oup.com/ecco-jcc/article/6/Supplement_1/S164/369091

P-015 YI Low-Dose Naltrexone Therapy Improves Active Ulcerative Colitis

Inflam Bowel Dis
01 December 2013
https://academic.oup.com/ibdjournal/search-results?page=1&q=Low-Dose%20Naltrexone%20Therapy%20Improves%20Active%20Ulcerative%20Colitis&fl_SiteID=6136&SearchSourceType=1&allJournals=1

P418 Low dose naltrexone in therapy resistant IBD, a case series

J Crohn's and Colitis
February 2014
https://www.gastrojournal.org/article/S0016-5085(14)61660-7/pdf

Tu1365 Low Dose Naltrexone in the Treatment of Crohn's Disease: A Case Series

Gastroenterology
April 2015
http://www.gastrojournal.org/article/S0016-5085(15)32952-8/abstract

Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial

Dig Dis Sci
July 2011
https://pubmed.ncbi.nlm.nih.gov/21380937/ 

Low-dose naltrexone for treatment of duodenal Crohn's disease in a pediatric patient

Inflamm Bowel Dis
September 2010
https://academic.oup.com/ibdjournal/article/16/9/1457/4628412

Low-dose naltrexone therapy improves active Crohn's disease

Am J Gastroenterol
April 2007
https://pubmed.ncbi.nlm.nih.gov/17222320/

Objectives: Endogenous opioids and opioid antagonists have been shown to play a role in healing and repair of tissues. In an open-labeled pilot prospective trial, the safety and efficacy of low-dose naltrexone (LDN), an opioid antagonist, were tested in patients with active Crohn's disease.